| A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis AG Granja, F Carrillo-Salinas, A Pagani, M Gómez-Cañas, R Negri, ... Journal of Neuroimmune Pharmacology 7 (4), 1002-1016, 2012 | 166 | 2012 |
| Prospects for cannabinoid therapies in basal ganglia disorders J Fernández‐Ruiz, M Moreno‐Martet, C Rodríguez‐Cueto, ... British journal of pharmacology 163 (7), 1365-1378, 2011 | 150 | 2011 |
| Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons A de Salas-Quiroga, J Díaz-Alonso, D García-Rincón, F Remmers, ... Proceedings of the National Academy of Sciences 112 (44), 13693-13698, 2015 | 144 | 2015 |
| Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling E Moreno, C Andradas, M Medrano, MM Caffarel, E Pérez-Gómez, ... Journal of Biological Chemistry 289 (32), 21960-21972, 2014 | 135 | 2014 |
| The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 … C Del Río, C Navarrete, JA Collado, ML Bellido, M Gómez-Cañas, ... Scientific reports 6 (1), 1-14, 2016 | 86 | 2016 |
| Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of … C García, M Gómez-Cañas, S Burgaz, B Palomares, Y Gómez-Gálvez, ... Journal of neuroinflammation 15 (1), 1-17, 2018 | 63 | 2018 |
| Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease P González-Naranjo, N Pérez-Macias, NE Campillo, C Pérez, VJ Arán, ... European journal of medicinal chemistry 73, 56-72, 2014 | 56 | 2014 |
| Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity P Morales, D Vara, M Goméz-Cañas, MC Zúñiga, C Olea-Azar, P Goya, ... European journal of medicinal chemistry 70, 111-119, 2013 | 55 | 2013 |
| Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer P Morales, S Blasco-Benito, C Andradas, M Gómez-Cañas, JM Flores, ... Journal of medicinal chemistry 58 (5), 2256-2264, 2015 | 44 | 2015 |
| Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties J Cumella, L Hernández-Folgado, R Girón, E Sánchez, P Morales, ... ChemMedChem 7 (3), 452, 2012 | 41 | 2012 |
| Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis P Morales, M Gómez-Cañas, G Navarro, DP Hurst, FJ Carrillo-Salinas, ... Journal of medicinal chemistry 59 (14), 6753-6771, 2016 | 38 | 2016 |
| VCE‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB2 receptor‐dependent … C Del Rio, I Cantarero, B Palomares, M Gómez‐Cañas, ... British journal of pharmacology 175 (19), 3813-3831, 2018 | 33 | 2018 |
| Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease S Burgaz, C García, M Gómez-Cañas, E Muñoz, J Fernández-Ruiz Molecules 24 (15), 2702, 2019 | 32 | 2019 |
| Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile M Gómez-Cañas, P Morales, L García-Toscano, C Navarrete, E Muñoz, ... Pharmacological research 110, 205-215, 2016 | 30 | 2016 |
| Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist … V Deiana, M Gómez-Cañas, MR Pazos, J Fernández-Ruiz, B Asproni, ... European journal of medicinal chemistry 112, 66-80, 2016 | 25 | 2016 |
| Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21 M Alvarado, J Decara, MJ Luque, L Hernandez-Folgado, ... Bioorganic & medicinal chemistry 21 (7), 1708-1716, 2013 | 24 | 2013 |
| Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists G Ragusa, M Gómez-Cañas, P Morales, DP Hurst, F Deligia, R Pazos, ... European journal of medicinal chemistry 101, 651-667, 2015 | 23 | 2015 |
| Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors B Palomares, M Garrido‐Rodriguez, C Gonzalo‐Consuegra, ... British journal of pharmacology 177 (17), 4034-4054, 2020 | 20 | 2020 |
| Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice S Burgaz, C García, M Gómez-Cañas, C Navarrete, A García-Martín, ... Molecular and Cellular Neuroscience 110, 103583, 2021 | 19 | 2021 |
| Identification of novel GPR55 modulators using cell-impedance-based label-free technology P Morales, LS Whyte, R Chicharro, M Gomez-Canas, MR Pazos, P Goya, ... Journal of medicinal chemistry 59 (5), 1840-1853, 2016 | 18 | 2016 |
Javier Fernández-RuizProfesor de Bioquímica, Universidad ComplutenseVerified email at ucm.es
